Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience [PDF]
Vojnosanitetski Pregled, 2010 Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region - Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML).
Ćojbašić Irena +1 more
doaj +1 more source
Paraneoplastic hypoglycaemia secondary to IGF-2 secretion from a metastatic gastrointestinal stromal tumour [PDF]
, 2020 We report the case of a 79-year-old male with previous history of non-Hodgkin's lymphoma in remission, who presented acutely to the Accident and Emergency department with recurrent episodes of hypoglycaemia.
Dimitriadis, Georgios K. +9 more
core +1 more source
Nail lichen planus associated with imatinib mesylate. [PDF]
JAAD Case RepAxler E +4 more
europepmc +4 more sources
Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. [PDF]
, 2011 OBJECTIVE: The origin of the mesenchymal cells responsible for the intimal fibrosis in systemic sclerosis (SSc) has not been fully identified. The present study was undertaken to investigate whether subendothelial mesenchymal cells may emerge through ...
Jimenez, Sergio A., Li, zhaodong
core +2 more sources
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018 Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT is inhibited by the KIT inhibitor imatinib ...
Eun Hyea Park +3 more
doaj +1 more source
Role for targeted resection in the multidisciplinary treatment of metastatic gastrointestinal stromal tumor [PDF]
, 2019 The management of advanced gastrointestinal stromal tumors (GISTs) has evolved in the modern era due to the discovery of c-kit mutations and the development of tyrosine kinase inhibitors (TKIs).
Feizpour, Cyrus +4 more
core +1 more source
A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]
, 2015 Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela +4 more
core +3 more sources
Imatinib mesylate causes hypopigmentation in the skin [PDF]
Cancer, 2003 AbstractBACKGROUNDImatinib mesylate is a tyrosine kinase inhibitor that targets the BCR‐ABL protein in CML, c‐kit (KIT) and platelet‐derived growth factor receptors. In clinical trials with imatinib mesylate, common side effects of nausea, emesis, diarrhea, periorbital edema, fluid retention, and myelosuppression have been documented.METHODSIn this ...
Hagop Kantarjian +4 more
openaire +3 more sources
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]
, 2009 Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
A Foudi +56 more
core +3 more sources
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
New England Journal of Medicine, 2002 BACKGROUND Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.
H. Kantarjian +31 more
semanticscholar +1 more source